Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Fred Aslan | $665,000 | $0 | $5,455,700 | $0 | $536,281 | $0 | $14,234 | $6,671,215 |
| Chief Executive Officer | ||||||||
| Jennifer Bush | 520,000 | 0 | 697,501 | 0 | 304,980 | 0 | 14,234 | 1,536,715 |
| Chief Operating Officer, Chief Legal Officer and Compliance Officer | ||||||||
| Christopher Horan | 490,000 | 0 | 638,236 | 0 | 287,385 | 0 | 234 | 1,415,855 |
| Chief Technical Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Fred Aslan | $6,671,215 | — | — | — |
| Jennifer Bush | 1,536,715 | — | — | — |
| Christopher Horan | 1,415,855 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Fred Aslan | RSU | 148,958 | — | $639,030 |
| Fred Aslan | RSU | 566,470 | — | 2,430,156 |
| Fred Aslan | RSU | 212,888 | — | 913,290 |
| Fred Aslan | RSU | 162,500 | — | 697,125 |
| Christopher Horan | RSU | 88,436 | — | 379,390 |
| Fred Aslan | RSU | 76,002 | — | 326,049 |
| Jennifer Bush | RSU | 13,680 | — | 58,687 |
| Jennifer Bush | RSU | 70,405 | — | 302,037 |
| Jennifer Bush | RSU | 60,371 | — | 258,992 |
| Christopher Horan | RSU | 48,750 | — | 209,138 |
| Jennifer Bush | RSU | 34,375 | — | 147,469 |
| Christopher Horan | RSU | 17,188 | — | 73,737 |
| Fred Aslan | RSU | 13,776 | — | 59,099 |
| Christopher Horan | RSU | 13,683 | — | 58,700 |
| Jennifer Bush | RSU | 7,400 | — | 31,746 |
| Jennifer Bush | RSU | 3,426 | — | 14,698 |
| Christopher Horan | RSU | 3,421 | — | 14,676 |
| Christopher Horan | RSU | 1,616 | — | 6,933 |
The company seeks to motivate and reward executives for achievements relative to corporate goals and expectations. Equity awards are considered an integral component of the overall compensation program to secure and retain services and align interests with stockholders.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | The company has implemented a Dodd-Frank Act-compliant clawback policy as required by SEC rules, and executives may be required to reimburse the company for incentive-based compensation in the event of financial restatement due to misconduct under Section 304 of the Sarbanes-Oxley Act. |
| Anti-hedging | The Insider Trading Policy prohibits directors, officers, consultants, and employees from engaging in derivatives securities or hedging transactions, including prepaid variable forward contracts, equity swaps, collars, and exchange funds. |
| Anti-pledging | The Insider Trading Policy prohibits pledging securities as collateral for a loan without prior approval from the Board and pre-clearance from the Chief Legal Officer or their designee. |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Artiva Biotherapeutics | 2025 | Fred Aslan | $665,000 | $5,455,700 | $0 | $536,281 | $6,671,215 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Fred Aslan | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 6,671,215. Filing ↗machine: r2 · c25 · span 611443–611452 |
| 2 | Section 01, Jennifer Bush | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 1,536,715. Filing ↗machine: r4 · c25 · span 630137–630146 |
| 3 | Section 01, Christopher Horan | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 1,415,855. Filing ↗machine: r6 · c25 · span 649122–649131 |
| 4 | Section 07, pay ratio | 10-K/A | 2026-04-30 | 0001193125-26-197115 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Artiva Biotherapeutics (subject), Section 10b CEO total | DEF 14A | 2026-08-03 | 0001193125-26-330563 | CEO total compensation as printed in Artiva Biotherapeutics's own proxy. As printed: 6,671,215. Filing ↗machine: r2 · c25 · span 611443–611452 |